Cadrenal Therapeutics Files 8-K on Warrants and Equity

Ticker: CVKD · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001937993

Sentiment: neutral

Topics: financing, equity, warrants

Related Tickers: CADL

TL;DR

CADL filed an 8-K detailing new warrants and equity sales - potential financing news.

AI Summary

Cadrenal Therapeutics, Inc. filed an 8-K on April 1, 2026, reporting a material definitive agreement and unregistered sales of equity securities. The filing includes exhibits detailing forms of new warrants, placement agent warrants, and a warrant inducement agreement, suggesting potential financing or strategic transactions.

Why It Matters

This filing indicates potential new financing or strategic partnerships for Cadrenal Therapeutics through the issuance of warrants, which could impact the company's capital structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves unregistered sales of equity and warrants, which can introduce dilution and uncertainty for existing shareholders.

Key Numbers

Key Players & Entities

FAQ

What type of material definitive agreement was entered into by Cadrenal Therapeutics?

The 8-K filing indicates the entry into a material definitive agreement, with exhibits detailing forms of new warrants, placement agent warrants, and a warrant inducement agreement, suggesting a financing or strategic transaction.

Were there any unregistered sales of equity securities reported?

Yes, Item 3.02 of the 8-K filing explicitly states 'Unregistered Sales of Equity Securities'.

What are the key exhibits attached to this 8-K filing?

The key exhibits include the form of a new warrant, the form of a placement agent warrant, and the form of a warrant inducement agreement.

When was this 8-K filing accepted by the SEC?

The 8-K filing was accepted by the SEC on April 1, 2026, at 07:40:36.

What is the business address and phone number for Cadrenal Therapeutics?

The business address is 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082, and the phone number is 904-300-0701.

Filing Stats: 2,346 words · 9 min read · ~8 pages · Grade level 13.7 · Accepted 2026-04-01 07:40:36

Key Financial Figures

Filing Documents

01. Entry into a Material Definitive

Item 1.01. Entry into a Material Definitive Agreement. Warrant Inducement Agreement and Issuance of New Warrants On March 31, 2026, Cadrenal Therapeutics, Inc. (the "Company") entered into a warrant inducement letter agreement (the "Inducement Agreement") with a holder (the "Holder") of the Company's warrants to purchase shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), issued in a private placement offering that closed on November 4, 2024 (the "Existing Warrants"). Pursuant to the Inducement Agreement, the Holder of the Existing Warrants agreed to exercise for cash the Existing Warrants to purchase up to an aggregate of 571,430 shares of Common Stock, at the adjusted exercise price of $4.50 per share (reduced from the initial exercise price of $16.50 per share). The offer and resale of the shares of Common Stock underlying the Existing Warrants (the "Existing Warrant Shares") have been registered pursuant to the Company's Registration Statement on Form S-3 (File No. 333-283226) (the "Registration Statement"). The Registration Statement is currently effective and, upon exercise of the Existing Warrants pursuant to the Inducement Agreement, will be effective for the issuance or sale, as the case may be, of the Existing Warrant Shares. The transactions contemplated by the Inducement Agreement is expected to close on April 1, 2026 (the "Closing Date"), subject to the satisfaction of customary closing conditions. The Company will receive aggregate gross proceeds of approximately $2.5 million from the exercise of the Existing Warrants, before deducting placement agent fees and other expenses payable by the Company. In consideration of the Holder's agreement to exercise the Existing Warrants (the "Warrant Exercise"), at the reduced exercise price of $4.50 per share (which is equal to the Minimum Price, as defined in Rule 5635(d)(1)(A) of The Nasdaq Stock Market, plus $0.25), in accordance with the Inducement Agreement, the Company

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. The disclosure regarding the New Warrants, the New Warrant Shares, the Placement Agent Warrants and the Placement Agent Warrant Shares set forth under Item 1.01 is incorporated by reference into this Item 3.02. None of the New Warrants, the New Warrant Shares, the Placement Agent Warrants or the Placement Agent Warrant Shares have been registered under the Securities Act, and none may be sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act .

03. Material Modification

Item 3.03. Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of this Current Report on Form 8-K, the information contained in Item 1.01 of this Current Report on Form 8-K and Exhibit 10.1 to this Current Report on Form 8-K regarding the New Warrants are incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 4.1 Form of New Warrant 4.2 Form of Placement Agent Warrant 10.1 Form of Warrant Inducement Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 1, 2026 CADRENAL THERAPEUTICS, INC. By: /s/ Quang X. Pham Name: Quang X. Pham Title: Chairman and Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing